Payment overview · 2025
General Payments
$92.53
5 reported records · 3 companies
Healthcare provider profile · identity verified
Tasneem Cheema, MD
Allopathic & Osteopathic Physicians|Internal Medicine · THE VILLAGES, FL · NPI 1740489707
Verified facts
What the public records show
CMS Open Payments records show Tasneem Cheema, MD received $92.53 in general payments during 2025 across 5 reported records.
Corcept Therapeutics accounted for 46.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Prolia.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $43.39 | 46.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.78 | 37.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.36 | 15.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $92.53 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $43.39 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.78 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.78 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.78 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PROLIA prolia |
2025 | Prolia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
119 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 885 | 274 |
| Atorvastatin Calcium | Atorvastatin Calcium | 802 | 282 |
| Simvastatin | Simvastatin | 703 | 223 |
| Amlodipine Besylate | Amlodipine Besylate | 602 | 206 |
| Methylprednisolone | Methylprednisolone | 581 | 400 |
| Lisinopril | Lisinopril | 516 | 167 |
| Losartan Potassium | Losartan Potassium | 503 | 166 |
| Gabapentin | Gabapentin | 454 | 165 |
| Omeprazole | Omeprazole | 406 | 141 |
| Escitalopram Oxalate | Escitalopram Oxalate | 386 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 375 | 130 |
| Metformin Hcl | Metformin Hcl | 323 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 320 | 128 |
| Hydrochlorothiazide | Hydrochlorothiazide | 283 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 276 | 96 |
| Alprazolam | Alprazolam | 275 | 83 |
| Baclofen | Baclofen | 254 | 149 |
| Pravastatin Sodium | Pravastatin Sodium | 234 | 74 |
| Trazodone Hcl | Trazodone Hcl | 234 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 226 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 71 |
| Allopurinol | Allopurinol | 186 | 56 |
| Azithromycin | Azithromycin | 168 | 141 |
| Duloxetine Hcl | Duloxetine Hcl | 161 | 59 |
| Montelukast Sodium | Montelukast Sodium | 157 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 157 | 54 |
| Sertraline Hcl | Sertraline Hcl | 144 | 48 |
| Ezetimibe | Ezetimibe | 138 | 45 |
| Synthroid | Levothyroxine Sodium | 133 | 42 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 131 | 108 |
| Citalopram Hbr | Citalopram Hydrobromide | 130 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 51 |
| Meloxicam | Meloxicam | 129 | 55 |
| Famotidine | Famotidine | 123 | 44 |
| Eliquis | Apixaban | 119 | 40 |
| Alendronate Sodium | Alendronate Sodium | 113 | 45 |
| Furosemide | Furosemide | 107 | 50 |
| Bupropion Xl | Bupropion Hcl | 103 | 39 |
| Tramadol Hcl | Tramadol Hcl | 103 | 38 |
| Carvedilol | Carvedilol | 99 | 36 |
| Metformin Hcl Er | Metformin Hcl | 98 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 38 |
| Atenolol | Atenolol | 85 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 42 |
| Potassium Chloride | Potassium Chloride | 80 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | 21 |
| Lorazepam | Lorazepam | 64 | 26 |
| Eszopiclone | Eszopiclone | 63 | 21 |
| Lovastatin | Lovastatin | 63 | 20 |
| Enalapril Maleate | Enalapril Maleate | 62 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 21 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 58 | 47 |
| Glipizide | Glipizide | 56 | 22 |
| Glimepiride | Glimepiride | 55 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 21 |
| Glipizide Er | Glipizide | 54 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 47 |
| Donepezil Hcl | Donepezil Hcl | 53 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 18 |
| Amoxicillin | Amoxicillin | 49 | 33 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | 17 |
| Fluconazole | Fluconazole | 46 | 33 |
| Prednisone | Prednisone | 43 | 19 |
| Clonazepam | Clonazepam | 42 | 15 |
| Valsartan | Valsartan | 42 | 18 |
| Warfarin Sodium | Warfarin Sodium | 42 | 12 |
| Buspirone Hcl | Buspirone Hcl | 41 | 14 |
| Jardiance | Empagliflozin | 41 | 20 |
| Memantine Hcl | Memantine Hcl | 41 | 11 |
| Ozempic | Semaglutide | 41 | 15 |
| Pregabalin | Pregabalin | 40 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | 14 |
| Sucralfate | Sucralfate | 39 | 21 |
| Bupropion Hcl | Bupropion Hcl | 38 | 13 |
| Estradiol | Estradiol | 38 | 20 |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 38 |
| Propranolol Hcl | Propranolol Hcl | 38 | 14 |
| Xarelto | Rivaroxaban | 38 | 12 |
| Fenofibrate | Fenofibrate | 37 | 12 |
| Valacyclovir | Valacyclovir Hcl | 37 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 30 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | 14 |
| Finasteride | Finasteride | 34 | 13 |
| Acyclovir | Acyclovir | 33 | 14 |
| Spironolactone | Spironolactone | 33 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 11 |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 12 |
| Celecoxib | Celecoxib | 29 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 20 |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 11 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 26 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 26 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Topiramate | Topiramate | 25 | 11 |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Prolia | Denosumab | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $92.53 · 5 records | Corcept Therapeutics | ABRYSVO, COMIRNATY, EVENITY, Korlym, PREVNAR 20, PROLIA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Prolia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error